Literature DB >> 29913155

Antifibrotic role of PGC-1α-siRNA against TGF-β1-induced renal interstitial fibrosis.

Jue-Long Wang1, Chin-Wang Chen2, Mu-Rou Tsai3, Shu-Fen Liu4, Tsung-Jeu Hung5, Wen-Teng Chang3, Ming-Der Shi6, Pei-Fang Hsieh7, Yu-Lin Yang8.   

Abstract

Peroxisome proliferator-activated receptor coactivator-1 alpha (PGC-1α) is a transcriptional coactivator that regulates energy metabolism and mitochondrial biogenesis. Recently, mitochondrial dysfunction has been indicated as an established risk factor for the development of renal fibrosis. However, whether PGC-1α is involved in the pathogenesis of renal fibrosis is unknown. In this study, we treated NRK-49F (normal rat kidney fibroblast) cells with transforming growth factor-beta 1 (TGF-β1) for 24 h to establish an in vitro fibrosis model. TGF-β1 induced the upregulation of type I collagen, fibronectin, TGF-β receptor I (TGFβ-RI), TGFβ-RII, Smad4, and pSmad2/3, as well as PGC-1α. NRK-49F cells transfected with pcDNA-PGC-1α showed significantly increased expression of fibronectin and type I collagen, as revealed by western blot assay. Interestingly, transfection with PGC-1α-siRNA caused a stark reversal of TGF-β1-induced cellular fibrosis, with concomitant suppression of fibronectin and type I collagen, as revealed by western blot and immunofluorescence assays. Moreover, SB431542 (TGFβ-RI), LY294002 (PI3K/Akt), and SB203580 (p38 MAPK), inhibitors of TGF-β-associated pathways, markedly suppressed TGF-β1-induced PGC-1α upregulation. These results implicate a role of PGC-1α in renal interstitial fibrosis mediated via the TGFβ-RI, PI3K/Akt, and p38 MAPK pathways. Our findings that PGC-1α-siRNA downregulates fibronectin and type I collagen suggest that it can be used as a novel molecular treatment for renal fibrosis.
Copyright © 2018. Published by Elsevier Inc.

Entities:  

Keywords:  Peroxisome proliferator-activated receptor coactivator-1 alpha(PGC-1α); Renal interstitial fibrosis; Transforming growth factor-beta 1 (TGF-β1)

Mesh:

Substances:

Year:  2018        PMID: 29913155     DOI: 10.1016/j.yexcr.2018.06.016

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  5 in total

Review 1.  Druggability of lipid metabolism modulation against renal fibrosis.

Authors:  Yuan-Yuan Chen; Xiao-Guang Chen; Sen Zhang
Journal:  Acta Pharmacol Sin       Date:  2021-05-14       Impact factor: 6.150

Review 2.  The Role of Cell Division Autoantigen 1 (CDA1) in Renal Fibrosis of Diabetic Nephropathy.

Authors:  LinLin Chen; Jiao Wu; Bin Hu; Changbai Liu; Hu Wang
Journal:  Biomed Res Int       Date:  2021-04-28       Impact factor: 3.411

3.  Depleted HDAC3 attenuates hyperuricemia-induced renal interstitial fibrosis via miR-19b-3p/SF3B3 axis.

Authors:  Langtao Hu; Kai Yang; Xing Mai; Jiali Wei; Chunyang Ma
Journal:  Cell Cycle       Date:  2022-01-13       Impact factor: 5.173

4.  Knockdown of c-MYC Controls the Proliferation of Oral Squamous Cell Carcinoma Cells in vitro via Dynamic Regulation of Key Apoptotic Marker Genes.

Authors:  Hussein Sabit; Huseyin Tombuloglu; Emre Cevik; Shaimaa Abdel-Ghany; Engy El-Zawahri; Amr El-Sawy; Sevim Isik; Ebtesam Al-Suhaimi
Journal:  Int J Mol Cell Med       Date:  2021-05-22

Review 5.  Signaling Pathways Involved in Diabetic Renal Fibrosis.

Authors:  Yuqing Zhang; Xiaomin Kang; Rongrong Zhou; Yuting Sun; Fengmei Lian; Xiaolin Tong
Journal:  Front Cell Dev Biol       Date:  2021-07-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.